Y-mAbs Therapeutics (YMAB) announced the appointment of Mary Tagliaferri, M.D. to the Company’s Board of Directors, effective February 29, 2024. Dr. Tagliaferri brings nearly 30 years of biopharmaceutical industry experience and oncology therapeutic development expertise to the Y-mAbs Board of Directors. Dr. Tagliaferri has a highly accomplished biotechnology career and is currently the Chief Medical Officer and Senior Vice President of Nektar Therapeutics (NKTR).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on YMAB:
- Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
- Y-Mabs Therapeutics Welcomes New Board Member, Dr. Tagliaferri
- Y-mAbs Therapeutics sees FY24 revenue $95M-$100M, consensus $96.27M
- Y-mAbs Therapeutics reports Q4 EPS (2c), consensus (20c)
- Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
